New River Pharmaceuticals Inc

New River Pharmaceuticals — UBS Global Pharmaceuticals Conference 2005

20 slides from New River Pharmaceuticals's conference presentation, May 23, 2005

  1. Slide 1: UBS Global Pharmaceuticals Conference

    Slide 1: UBS Global Pharmaceuticals Conference

    N E W R I V E R PHARMACEUTICALS UBS Global Pharmaceuticals Conference May 23, 2005 RJ Kirk (Chairman and CEO) Krish Krishnan (CFO/COO) N E W R I V E R PHARMACEUTICALS

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    N E W R I V E R PHARMACEUTICALS Forward Looking Statements This presentation may contain forward-looking statements that reflect management's current views as to the Company's clinical trials, regulatory approval process, product development, research programs and other future events and operations.

  3. Slide 3: Investment Thesis

    Slide 3: Investment Thesis

    N E W R I V E R PHARMACEUTICALS Investment Thesis A platform technology yielding proprietary products that offer significant clinical advantages with low technical risk and short development pathway, facing timely market demand, in a favorable regulatory climate.

  4. Slide 4: Pipeline

    Slide 4: Pipeline

    N E W R I V E R PHARMACEUTICALS Pipeline n NRP104 (Carrierwave TM amphetamine): Phase 3 efficacy study completed with an anticipated NDA filing date by the end of 2005 n NRP290 (Carrierwave TM hydrocodone): Anticipate filing an IND in Q2 2005 n NRP369 (Carrierwave TM oxycodone): Anticipate filing an

  5. Slide 5: Business Overview

    Slide 5: Business Overview

    N E W R I V E R PHARMACEUTICALS Business Overview n Phase 3 efficacy study on NRP104, a conditionally bioreversible derivative of amphetamine, meets primary and secondary endpoint n Successful completion of NRP104 collaboration agreement with Shire Pharmaceuticals ("Shire") n Anticipated timeline on

  6. Slide 6: Collaboration Agreement with Shire

    Slide 6: Collaboration Agreement with Shire

    N E W R I V E R PHARMACEUTICALS Collaboration Agreement with Shire n New River primarily responsible for clinical and manufacturing development n Shire primarily responsible for commercialization; leverages Shire's CNS expertise and leadership in ADHD market n Global product potential n Profit share

  7. Slide 7: The U.S. ADHD Market Opportunity

    Slide 7: The U.S. ADHD Market Opportunity

    N E W R I V E R PHARMACEUTICALS The U.S. ADHD Market Opportunity (1) n CAGR 2002-2009 = 13.6% n 12 million potential customers in the United States with 78.3% of the market still untapped n Competitive factors -- drug side effects, long term safety and dosing convenience n Abuse is a growing concern

  8. Slide 8: The U.S. Pain Market

    Slide 8: The U.S. Pain Market

    N E W R I V E R PHARMACEUTICALS The U.S. Pain Market (1) The Pain Market ($19 billion in 2003; CAGR = 9.8%) Chronic Pain (NRP369) Acute Pain (NRP290) Duration: Typically lasts < 1 month Examples: Post-operative, obstetric, burns and truma Treatment: Opioids (hydrocodone), NSAIDS and analgesics Durat

  9. Slide 9: NRP104.301

    Slide 9: NRP104.301

    N E W R I V E R PHARMACEUTICALS NRP104.301

  10. Slide 10: NRP104: Overview

    Slide 10: NRP104: Overview

    N E W R I V E R PHARMACEUTICALS NRP104: Overview n A conditionally bioreversible derivative of d-amphetamine n Non-clinical and clinical studies to date have met their desired objectives n Phase 2 clinical study l Both NRP104 and Adderall XR demonstrated robust efficacy when compared to placebo, as

  11. Slide 11: NRP104.301 (Study Design)

    Slide 11: NRP104.301 (Study Design)

    N E W R I V E R PHARMACEUTICALS NRP104.301 (Study Design) Screening Washout (1 week) Randomized Treatment (4 weeks) Placebo: 0-0-0-0 30mg: 30-30-30-30 50mg: 30-50-50-50 70mg: 30-50-70-70 Study Exit Patient Eligibility n Children with either hyperactive or combined type of ADHD n Age 6 to 12 inclusiv

  12. Slide 12: NRP104.301 (Disease and Prior Treatment)

    Slide 12: NRP104.301 (Disease and Prior Treatment)

    N E W R I V E R PHARMACEUTICALS NRP104.301 (Disease and Prior Treatment) Placebo 30mg 50mg 70mg # of Patients ADHD Type/combined 96% 94% 96% 97% Age at ADHD onset 7.6 6.9 7.0 7.0 Years since Diagnosis 1.8 2.1 2.0 1.8 Immediate Prior Rx-Amphetamines* 8% 10% 10% 3% Immediate Prior Rx-MPH* 17% 20% 18%

  13. Slide 13: NRP104.301 Efficacy (ADHD-RS)

    Slide 13: NRP104.301 Efficacy (ADHD-RS)

    N E W R I V E R PHARMACEUTICALS NRP104.301 Efficacy (ADHD-RS) ** p<0.0001 (adjusted Dunnett test compared to placebo following ANCOVA with baseline score as covariate) ** ** ** ADHD Rating Scale: ITT Population at Endpoint (Primary Efficacy)

  14. Slide 14: NRP104.301 Efficacy (CPRS ADHD Index)

    Slide 14: NRP104.301 Efficacy (CPRS ADHD Index)

    N E W R I V E R PHARMACEUTICALS NRP104.301 Efficacy (CPRS ADHD Index) ** p<0.0001 (adjusted Dunnett test compared to placebo following ANCOVA with baseline score as covariate) ** ** ** CPRS ADHD Index: ITT Population at Endpoint in the Morning (10am)

  15. Slide 15: NRP104.301 Efficacy (CPRS ADHD Index)

    Slide 15: NRP104.301 Efficacy (CPRS ADHD Index)

    N E W R I V E R PHARMACEUTICALS NRP104.301 Efficacy (CPRS ADHD Index) ** p<0.0001 (adjusted Dunnett test compared to placebo following ANCOVA with baseline score as covariate) ** ** ** CPRS ADHD Index: ITT Population at Endpoint in the Afternoon (2pm)

  16. Slide 16: NRP104.301 Efficacy (CPRS ADHD Index)

    Slide 16: NRP104.301 Efficacy (CPRS ADHD Index)

    N E W R I V E R PHARMACEUTICALS NRP104.301 Efficacy (CPRS ADHD Index) ** p<0.0001 (adjusted Dunnett test compared to placebo following ANCOVA with baseline score as covariate) ** ** ** CPRS ADHD Index: ITT Population at Endpoint in the Evening (6pm)

  17. Slide 17: NRP104.301 Efficacy (CGI)

    Slide 17: NRP104.301 Efficacy (CGI)

    N E W R I V E R PHARMACEUTICALS NRP104.301 Efficacy (CGI) CGI: Improvement from Baseline (ITT Population) ** p<0.0001 (CMH test compared to placebo) ** ** ** ** **

  18. Slide 18: NRP104.301 Safety (Adverse Events by Week)

    Slide 18: NRP104.301 Safety (Adverse Events by Week)

    N E W R I V E R PHARMACEUTICALS NRP104.301 Safety (Adverse Events by Week) Week Week Week Week Week Week Week Week Preferred Term Placebo (n=72) Active Treatments (n=218) Placebo (n=69) Active Treatments (n=207) Placebo (n=62) Active Treatments (n=194) Placebo (n=56) Active Treatments (n=181) Abdomi

  19. Slide 19: NRP104.301 (Conclusion)

    Slide 19: NRP104.301 (Conclusion)

    N E W R I V E R PHARMACEUTICALS NRP104.301 (Conclusion) n Each of the NRP104 doses (30, 50, or 70 mg/day) demonstrated robust efficacy compared to placebo, as shown by ADHD-RS (the primary endpoint). n Each of the active doses demonstrated robust efficacy in the morning (10am), afternoon (2pm), and

  20. Slide 20: PHARMACEUTICALS

    Slide 20: PHARMACEUTICALS

    N E W R I V E R PHARMACEUTICALS

Source: SEC EDGAR · 8-K filed May 23, 2005

More decks from New River Pharmaceuticals Inc